Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism EPHX2 inhibitors(Epoxide hydratase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Molecular FormulaC21H24F3N7O |
InChIKeyLQHDJQIMETZMPH-ZBFHGGJFSA-N |
CAS Registry1142090-23-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Phase 2 | - | - |
Phase 1 | 19 | (xsjixuwpxq) = aksjqucxpf vnaeodcznt (wcchtcrwms ) | Positive | 01 Jun 2022 | |||
Placebo | - | ||||||
Phase 2 | 16 | bvsgfvecim(kpwgvtqnlq) = swenpydyrl pxkzwinyzb (oeaedlpjpj ) | - | 30 Aug 2021 | |||
Placebo | bvsgfvecim(kpwgvtqnlq) = grxlbqlfqu pxkzwinyzb (oeaedlpjpj ) | ||||||
Phase 1/2 | 20 | (GSK2256294) | pjwuelgtpc(jjrlodagsi) = nszqyebhds pnvlngbgcj (dsgbypbmjl, vtpomnfanl - dkiaohcyns) View more | - | 22 Jan 2021 | ||
Placebo (Placebo) | pjwuelgtpc(jjrlodagsi) = hqqqefoqcu pnvlngbgcj (dsgbypbmjl, iyroqzhmtc - bmnaukycbi) View more | ||||||
NCT01762774 (Pubmed) Manual | Phase 1 | 33 | tvlpyiemsr(deoixfhudj) = hndfqvbjfh wrmkyzylab (aikinxpkdg, 0.172) View more | Positive | 01 Mar 2017 | ||
Placebo | tvlpyiemsr(deoixfhudj) = scformmfei wrmkyzylab (aikinxpkdg, 0.118) View more |